ETAP-Lab is an independent Contract Research Organization (CRO)
ETAP-Lab provides preclinical pharmacology and research services, as well as scientific expertise, to Pharmaceutical and Agro-Food industries. Our activity focuses on In Vivo models of pathologies and toxicology studies in rodents to support drug and nutraceutic R&D for our sponsors.
Since the foundation in 1991, ETAP-Lab’s Scientists have an in-depth expertise in pathology modeling with rodents. By respecting rodent chronobiology and natural behaviors, ETAP-Lab proposes research models with added translational value. All our models are customizable and original specific models can be set-up and validated on request.
ETAP-Lab had an instrumental position in Ingredia's projects and successfully predicted in mice the efficacy of Pep2Dia, a new bioactive ingredient expected to reduce postprandial blood sugar levels. Ingredia